arrow
G

Guillaume P. Andrieu

hôpital necker enfants-malades
H指数:19
被引数:1,325

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Anti-thymocyte globulin triggers TNF-dependent cell death in T-cell acute lymphoblastic leukemia

抗胸腺细胞球蛋白触发T细胞急性淋巴细胞白血病中TNF依赖性细胞死亡

2026-09-190
OAAI
Homeodomain-driven oncogenic diversion to a γδTCR phenotype in T-cell Acute Lymphoblastic Leukemia

T细胞急性淋巴细胞白血病中同源域驱动的致癌转移至 γ δ tcr表型

Blood
IF23.1
2026-01-290
PRE
LEF1 intragenic deletion induces a dominant-negative isoform and unveils a Wnt/β3-catenin vulnerability in T-ALL

LEF1基因内缺失诱导产生显性负效异构体,并揭示T-ALL中Wnt/β3-连环蛋白的易损性。

Blood
IF23.1
2025-08-280
PRE
Towards methylation-based redefinition of TAL1 positive T-cell acute lymphoblastic leukaemia (T-ALL)

基于甲基化对TAL1阳性T细胞急性淋巴细胞白血病(T-ALL)的重新定义

Leukemia
IF13.4
2025-08-080
PRE
APR-246 Overcomes Resistance to Asparaginase in Lymphoid Malignancies By Targeting Metabolic Cell Vulnerabilities

APR-246通过靶向代谢细胞易损性克服淋巴恶性肿瘤中天冬酰胺酶的耐药性

BLOOD
IF23.1
2024-11-050
PRE
DNA methylation as a new tool for the differential diagnosis between T-LBL and lymphocyte-rich thymoma
2024-09-270
OA
Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
2024-04-242
PRE
PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
2023-10-271
PRE
From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia
2023-05-296
OAAI
Harnessing the MYB-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL

利用MYB依赖性TAL1 5' 超级增强子进行t-all的靶向治疗

2023-01-1810
OAAI
Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL
2021-05-0313
OAAI
Blueprint of human thymopoiesis reveals molecular mechanisms of stage-specific TCR enhancer activation

人类胸腺生成蓝图揭示了阶段特异性TCR增强子激活的分子机制

2020-07-1518
OAAI